Therapy. Statins and liver disease: from concern to 'wonder' drugs? (Q41240691)

28 September 2017

Therapy. Statins and liver disease: from concern to 'wonder' drugs? (English)

1 reference

28 September 2017

Jaume Bosch

1

1 reference

28 September 2017

Xavier Forns

series ordinal

2

1 reference

28 September 2017

language of work or name

English

0 references

publication date

12 May 2015

1 reference

Nature Reviews Gastroenterology & Hepatology

28 September 2017

1 reference

28 September 2017

12

1 reference

28 September 2017

6

1 reference

28 September 2017

320-321

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2015.78

28 September 2017

0 references

cites work

Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.78

HCV and host lipids: an intimate connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.78

Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.78

Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.78

Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.78

Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.78

Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.78

KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.78

Hepatitis C virus life cycle and lipid metabolism

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25963509

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRGASTRO.2015.78

1 reference

Dimensions Publication ID

28 September 2017

0 references

1 reference